Generation of a Monoclonal Antibody Agonist to Toll-Like Receptor 5
Generation of a Monoclonal Antibody Agonist to Toll-Like Receptor 5
批准号:
7746561
负责人:
Olga B Chernova
金额:
$10.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2010-06-30
关键词:
AcuteAdjuvantAdverse effectsAgonistAnimalsAntibodiesApoptosisApoptosis InhibitorApoptoticAttentionBenignBindingBlood CellsCancer PatientCancerousCell LineCell SurvivalCellsClinicalCollectionComplement Factor BCytokine SignalingCytoprotectionDataDevelopmentDoseDrug EvaluationDrug usageEffectivenessEngineeringEpithelialEthicsEvolutionFamily memberFlagellinFlow CytometryFutureGastrointestinal tract structureGene ExpressionGenerationsGoalsHematopoietic SystemHost Defense MechanismHumanHybridomasIL8 geneImmune responseImmunityImmunomodulatorsImmunoprecipitationIn VitroInflammationInflammatoryInjection of therapeutic agentIntestinesLigandsMacaca mulattaMass Spectrum AnalysisMeasuresMediatingMedicalMicrobeMolecularMonoclonal AntibodiesMononuclearMusNatural ImmunityNormal CellNormal tissue morphologyNuclearNull LymphocytesOutcomeParkinson DiseasePatternPharmaceutical PreparationsPhasePhase I Clinical TrialsPreclinical Drug DevelopmentProcessPropertyProteinsRadiationRadiation SyndromesRadiation therapyReactive Oxygen SpeciesReceptor SignalingRecombinantsReporterReporter GenesResistanceSalmonellaScreening procedureSignal PathwaySignal TransductionSpecificityStressTLR4 geneTestingTherapeuticTherapeutic IndexTherapeutic StudiesTissuesToll-Like Receptor 5Toll-like receptorsToxic effectVaccinationVariantWestern Blottinganimal efficacyantimicrobialbasebiodefensecancer cellcancer radiation therapycancer therapycell typechemokinechemotherapycomparative efficacycross reactivitycytokinedrug developmentdrug efficacyefficacy trialimmunogenicimmunogenicityimprovedin vivointerestirradiationmicroorganismnonhuman primatepolypeptidepre-clinicalpreclinical studyprogramspublic health relevanceradiation adverse effectresearch studyresponsetissue regeneration
中文摘要
描述(由申请人提供):用细菌鞭毛蛋白进行全身治疗,这是一种toll样受体5 (TLR5)激动剂,通过激活核因子-(B) (NF-(B))提供抗高剂量辐射的保护。NF-(B)信号可以诱导多种因素促进细胞存活和组织再生,包括细胞凋亡抑制剂、活性氧清除剂和细胞因子。我们设计了CBLB502,一种优化的鞭毛蛋白衍生物,具有降低的免疫原性,用于开发作为放射保护剂。虽然CBLB502目前处于生物防御应用的1期试验阶段,但它也有望广泛应用于医疗领域,包括减少抗癌放疗和化疗的不良副作用。然而,反复给药CBLB502可诱导中和性免疫反应,从而限制其有效性。为了开发免疫原性降低的TLR5激动剂,我们制备了单克隆抗人TLR5抗体,该抗体在结合时激活TLR5。本提案的重点是生成的激动抗体的详细功能和免疫化学特征,以便选择最有效和特异性地激活人类上皮细胞和单核细胞中的TLR5的候选抗体,并激活通常用于临床前药物评估的其他物种的TLR5。在该项目的下一阶段,将对选定的抗体进行体内辐射防护功效评估。
英文摘要
DESCRIPTION (provided by applicant): Systemic treatment with the bacterial flagellin protein, a Toll-like receptor 5 (TLR5) agonist, provides protection against high dose radiation through activation of nuclear factor-(B (NF-(B). NF-(B signaling induces multiple factors that contribute to cell survival and tissue regeneration, including apoptosis inhibitors, reactive oxygen species scavengers, and cytokines. We have engineered CBLB502, an optimized flagellin derivative with reduced immunogenicity, for development as a radioprotectant. While CBLB502 is currently in Phase 1 trials for biodefense applications, it is also expected to have a wide range of medical applications, including reduction of the adverse side effects of anti-cancer radio- and chemotherapy. However, repeated administration of CBLB502 could induce a neutralizing immune response that would limit its effectiveness. To develop alternative TLR5 agonists with reduced immunogenicity, we generated monoclonal anti-human-TLR5 antibodies that activate TLR5 upon binding. This proposal is focused on detailed functional and immunochemical characterization of the generated agonistic antibodies in order to select the candidates that most potently and specifically activate TLR5 in both epithelial and monocytic cells of human origin and also activate TLR5 from other species commonly used in pre-clinical drug evaluation. In the next phase of the project, the selected antibodies will be evaluated for radioprotective efficacy in vivo.
PUBLIC HEALTH RELEVANCE: Pharmacological activation of TLR5 with CBLB502, a derivative of the bacterial flagellin protein, is a powerful approach to protection of sensitive tissues from acute radiation exposure and other types of stress. However, prolonged treatment with CBLB502 for some medical applications (such as protection of normal tissues during anti-cancer radiotherapy) could induce undesirable immune responses. Alternative TLR5 agonists with reduced immunogenicity, such as the agonistic antibodies that are the subject of this proposal, would be ideal drugs for such applications, potentially leading to clinical impacts such as improvement of the therapeutic index of radiation therapy
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New type of androgen receptor inhibitors for prostate cancer treatment
-
批准号:7805324
-
项目类别:
-
资助金额:$10.74万
-
财政年份:2010
-
负责人:Olga B Chernova
-
依托单位:
Novel Hematopoietic Conditioning Agents for Treatment of Hematological Diseases
-
批准号:7805312
-
项目类别:
-
资助金额:$11.29万
-
财政年份:2010
-
负责人:Olga B Chernova
-
依托单位:
海外基金